Louisiana proposes tapping a century-old patent law to cut hepatitis C drug prices

Washington Post, 2 May 2017
Authors: Sarah Jane, Tribble Kaiser
“Continuing public concerns over high-priced hepatitis C drugs are taking a new twist as Louisiana’s top health official proposes using an obscure federal patent law to get the medicines at a much lower cost. If successful, other states could reap the benefits. Covering treatment for the 35,000 uninsured and Medicaid-dependent residents with hepatitis C would cost the state $764 million given current drug costs.”
Find article here.